Dollars may not buy as many QALYs as we think: A problem with defining quality-of-life adjustments

被引:95
作者
Fryback, DG [1 ]
Lawrence, WF [1 ]
机构
[1] UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA
关键词
QALY; quality-adjusted life years; utility; quality-of-life assessment; cost-utility analysis; cost-effectiveness methodology;
D O I
10.1177/0272989X9701700303
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The scale of health slate quality that should be used to compute quality-adjusted life years (QALYs) ranges from 0 (death) to 1.0 (excellent health); this is called the ''Q'' scale. But many cost-utility analyses (CUAs) in the literature use the upper anchor of the scale to denote only the absence of the particular health condition under investigation, and weight the disease state proportional to this endpoint: these are called ''q'' scales. Computations using q-scale health-state weights ignore the fact that the average patient is still subject to chronic and acute conditions comorbid with the condition being analyzed; the absence of a particular condition is not in general the same as excellent health, i.e., the Q scale is longer than a q scale. CUAs based on q scales yield 'qALYs.'' Incremental $/qALY ratios are generally lower than $/QALY ratios; in the example presented, $/qALY must be inflated by about 15% to yield $/QALY. Other CUAs correctly weight disease states using the Q scale, but erroneously assign a quality weight of 1.0 to absence of the disease in the CUA computations. The results of such analyses are called ''NP-QALYs,'' as the correction factor to compute QALYs is not a simple proportional adjustment. The authors suggest that analysts doing cost-utility analyses without access to primary data from treated patients use average age-specific health-related quality-of-life weights from population-based studies to represent the state of not having a particular disease. Consumers of CUAs should closely examine the nature of the QALYs in any published analyses before making decisions based on their results.
引用
收藏
页码:276 / 284
页数:9
相关论文
共 25 条
[1]  
BERTHELOT JM, 1992, P 6 M INT NETW HLTH
[2]  
BOSCH JL, 1995, SMDM NEWSLETTER, V6, P6
[3]   SHOULD THE ELDERLY RECEIVE CHEMOTHERAPY FOR NODE-NEGATIVE BREAST-CANCER - A COST-EFFECTIVENESS ANALYSIS EXAMINING TOTAL AND ACTIVE LIFE-EXPECTANCY OUTCOMES [J].
DESCH, CE ;
HILLNER, BE ;
SMITH, TJ ;
RETCHIN, SM .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :777-782
[4]  
Drummond M, 1987, METHODS EC EVALUATIO
[5]   FOOT INFECTIONS IN DIABETIC-PATIENTS - DECISION AND COST-EFFECTIVENESS ANALYSES [J].
ECKMAN, MH ;
GREENFIELD, S ;
MACKEY, WC ;
WONG, JB ;
KAPLAN, S ;
SULLIVAN, L ;
DUKES, K ;
PAUKER, SG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (09) :712-720
[6]  
ERICKSON P, 1995, HLTH PEOPLE 2000
[7]   A DECISION-ANALYSIS OF ALTERNATIVE TREATMENT STRATEGIES FOR CLINICALLY LOCALIZED PROSTATE-CANCER [J].
FLEMING, C ;
WASSON, JH ;
ALBERTSEN, PC ;
BARRY, MJ ;
WENNBERG, JE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (20) :2650-2658
[8]   OPTIMAL MANAGEMENT STRATEGIES FOR HIV-INFECTED PATIENTS WHO PRESENT WITH COUGH OR DYSPNEA - A COST-EFFECTIVENESS ANALYSIS [J].
FREEDBERG, KA ;
TOSTESON, ANA ;
COTTON, DJ ;
GOLDMAN, L .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1992, 7 (03) :261-272
[9]   THE BEAVER DAM HEALTH OUTCOMES STUDY - INITIAL CATALOG OF HEALTH-STATE QUALITY FACTORS [J].
FRYBACK, DG ;
DASBACH, EJ ;
KLEIN, R ;
KLEIN, BEK ;
DORN, N ;
PETERSON, K ;
MARTIN, PA .
MEDICAL DECISION MAKING, 1993, 13 (02) :89-102
[10]  
GOLD MR, 1994, MED DECIS MAKING, V14, P431